Cargando…

Improvement of survival for non-small cell lung cancer over time

Non-small cell lung cancer (NSCLC) is the main histological subtype of lung cancer, which is the leading cause of cancer death. It is unclear whether the improved survival seen at high-volume centers applies to the general population and, more importantly, whether the improvement in lung cancer surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Wenjie, Yu, Xinnian, Mao, Qixing, Xia, Wenying, Wang, Anpeng, Dong, Gaochao, Chen, Bing, Ma, Weidong, Xu, Lin, Jiang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587133/
https://www.ncbi.nlm.nih.gov/pubmed/28919778
http://dx.doi.org/10.2147/OTT.S145036
_version_ 1783261942424535040
author Xia, Wenjie
Yu, Xinnian
Mao, Qixing
Xia, Wenying
Wang, Anpeng
Dong, Gaochao
Chen, Bing
Ma, Weidong
Xu, Lin
Jiang, Feng
author_facet Xia, Wenjie
Yu, Xinnian
Mao, Qixing
Xia, Wenying
Wang, Anpeng
Dong, Gaochao
Chen, Bing
Ma, Weidong
Xu, Lin
Jiang, Feng
author_sort Xia, Wenjie
collection PubMed
description Non-small cell lung cancer (NSCLC) is the main histological subtype of lung cancer, which is the leading cause of cancer death. It is unclear whether the improved survival seen at high-volume centers applies to the general population and, more importantly, whether the improvement in lung cancer survival was just a consequence of improved screening work. Data from the Surveillance, Epidemiology, and End Results (SEER) registry was used to identify 405,580 patients with NSCLC diagnosed from 1988 to 2008. The patients were divided into four groups according to the year of diagnosis. Trends of clinical characteristics were analyzed to reflect the progress of screening work. Five-year relative survivals in various subgroups were compared. The results indicated that proportion of aged, advanced, and non-surgical patients increased, whereas patients with lymph node metastasis and high histology grade decreased. Improvements in all stages of NSCLC patients were demonstrated, with relatively more significant gains for patients with localized and regional disease. After potentially curative surgical resection, remarkable improvements were observed in both cohorts with time (surgical: 52.00%–63.00%; non-surgical: 6.10%–13.50%). Specifically, patients who underwent pneumonectomy, lobectomy/bilobectomy, and partial/wedge/segmental resection all presented better survival rates. Our SEER analysis demonstrated improvements among patients in all stages of NSCLC that were deemed attributable to improved therapy and medical care for NSCLC rather than improved screening work.
format Online
Article
Text
id pubmed-5587133
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55871332017-09-15 Improvement of survival for non-small cell lung cancer over time Xia, Wenjie Yu, Xinnian Mao, Qixing Xia, Wenying Wang, Anpeng Dong, Gaochao Chen, Bing Ma, Weidong Xu, Lin Jiang, Feng Onco Targets Ther Original Research Non-small cell lung cancer (NSCLC) is the main histological subtype of lung cancer, which is the leading cause of cancer death. It is unclear whether the improved survival seen at high-volume centers applies to the general population and, more importantly, whether the improvement in lung cancer survival was just a consequence of improved screening work. Data from the Surveillance, Epidemiology, and End Results (SEER) registry was used to identify 405,580 patients with NSCLC diagnosed from 1988 to 2008. The patients were divided into four groups according to the year of diagnosis. Trends of clinical characteristics were analyzed to reflect the progress of screening work. Five-year relative survivals in various subgroups were compared. The results indicated that proportion of aged, advanced, and non-surgical patients increased, whereas patients with lymph node metastasis and high histology grade decreased. Improvements in all stages of NSCLC patients were demonstrated, with relatively more significant gains for patients with localized and regional disease. After potentially curative surgical resection, remarkable improvements were observed in both cohorts with time (surgical: 52.00%–63.00%; non-surgical: 6.10%–13.50%). Specifically, patients who underwent pneumonectomy, lobectomy/bilobectomy, and partial/wedge/segmental resection all presented better survival rates. Our SEER analysis demonstrated improvements among patients in all stages of NSCLC that were deemed attributable to improved therapy and medical care for NSCLC rather than improved screening work. Dove Medical Press 2017-08-29 /pmc/articles/PMC5587133/ /pubmed/28919778 http://dx.doi.org/10.2147/OTT.S145036 Text en © 2017 Xia et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Xia, Wenjie
Yu, Xinnian
Mao, Qixing
Xia, Wenying
Wang, Anpeng
Dong, Gaochao
Chen, Bing
Ma, Weidong
Xu, Lin
Jiang, Feng
Improvement of survival for non-small cell lung cancer over time
title Improvement of survival for non-small cell lung cancer over time
title_full Improvement of survival for non-small cell lung cancer over time
title_fullStr Improvement of survival for non-small cell lung cancer over time
title_full_unstemmed Improvement of survival for non-small cell lung cancer over time
title_short Improvement of survival for non-small cell lung cancer over time
title_sort improvement of survival for non-small cell lung cancer over time
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587133/
https://www.ncbi.nlm.nih.gov/pubmed/28919778
http://dx.doi.org/10.2147/OTT.S145036
work_keys_str_mv AT xiawenjie improvementofsurvivalfornonsmallcelllungcancerovertime
AT yuxinnian improvementofsurvivalfornonsmallcelllungcancerovertime
AT maoqixing improvementofsurvivalfornonsmallcelllungcancerovertime
AT xiawenying improvementofsurvivalfornonsmallcelllungcancerovertime
AT wanganpeng improvementofsurvivalfornonsmallcelllungcancerovertime
AT donggaochao improvementofsurvivalfornonsmallcelllungcancerovertime
AT chenbing improvementofsurvivalfornonsmallcelllungcancerovertime
AT maweidong improvementofsurvivalfornonsmallcelllungcancerovertime
AT xulin improvementofsurvivalfornonsmallcelllungcancerovertime
AT jiangfeng improvementofsurvivalfornonsmallcelllungcancerovertime